Navigation Links
Allegheny General Hospital Study Suggests Use of Image Guided Intensity Modulated Radiation Therapy Reduces Risk of Impotency in Men Needing Radiation after Prostate Cancer Surgery
Date:11/2/2010

PITTSBURGH, Nov. 2, 2010 /PRNewswire-USNewswire/ -- Men battling prostate cancer who receive Image Guided Intensity Modulated Radiation Therapy after undergoing prostatectomy have an excellent chance of retaining sexual function, according to a study by Allegheny General Hospital (AGH) cancer specialists presented this week at the annual meeting of the American Society for Therapeutic Radiation and Oncology in San Diego.

Each year in the United States about 200,000 men are diagnosed with prostate cancer. It is the second most common cancer among men, second only to skin cancer.  Most men with prostate cancer are over age 65, and the disease disproportionately strikes African-American men.

"Any cancer diagnosis can impact quality of life, but a prostate cancer diagnosis can be particularly difficult for men because impotence is a common side effect of treatment," said Russell Fuhrer, MD. "While recent improvements have made loss of potency less common after prostate cancer therapy, men must still take this complication into account as they decide on a treatment plan."

The AGH study, "Preservation of Sexual Function After High-Dose Post Prostatectomy Image Guided Intensity-Modulated Radiation Therapy (IMRT)," looked at 33 patients who underwent prostate removal surgery using open or robotic nerve-sparing techniques, followed by Image Guided IMRT radiotherapy.

Image Guided IMRT is an advanced type of radiotherapy in which computer-controlled linear accelerators direct radiation precisely to the tumor, sparing surrounding healthy tissues. Used extensively to treat prostate cancer, Image guided IMRT allows a higher, more focused and effective dose of radiation to the tumor.

Before radiotherapy, the men assessed their sexual function using a self-administered questionnaire called SHIM, Sexual Health Inventory for Men. For men who qualified as potent, researchers again used the SHIM test to measure their potency after radiotherapy.

Among men in the AGH study who were potent at the beginning of radiation therapy, 71 percent maintained potency at 27 months following radiotherapy with Image guided IMRT.

"These results suggest that men who must undergo radiotherapy following a prostatectomy can be confident that they have an excellent chance of maintaining potency after treatment when Image guided IMRT is used," Dr. Fuhrer said.


'/>"/>
SOURCE West Penn Allegheny Health System
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pennsylvania Agriculture Department Issues Quarantine for Allegheny County Horse Stable
2. Allegheny General Hospital Performs First Liver Transplant
3. Accuray Hires General Manager for the Asia Pacific Region
4. General Dynamics Awarded Contract to Outfit and Transition U.S. Army Medical Facilities
5. Lotus Pharmaceuticals Retains Sichenzia Ross Friedman Ference LLP as General Legal Counsel
6. North American Spine Partners With University General Hospital to Bring Back Pain Relief to Houston Patients
7. US Oncology Announces Addition of John Osborn as EVP & General Counsel and Asif Ahmad as EVP of Technology Services
8. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
9. Vanda Pharmaceuticals Adds Former U.S. Surgeon General, Steven Galson, to its Board of Directors
10. Xacore Partners With ESSE, Headed by Retired Army Four Star General, to Tackle Military Hearing Loss
11. Acuo Technologies Announces Implementation and Acceptance of Acuos DICOM Services Grid(TM) With Lancaster General Hospital
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... -- According to a new market research ... by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by Application (Drug ... Hospitals/ Clinics) - Forecast to 2021", published by MarketsandMarkets, ... the forecast period of 2016 to 2021. This market ... from USD 117.3 Million in 2016, at a CAGR ...
(Date:5/25/2016)... Germany and GERMANTOWN, Maryland ... N.V. (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) ... and co-development agreement with Therawis Diagnostics GmbH to develop and ... to develop and market PITX2 as a marker to predict ... breast cancer patients. "We are pleased to partner ...
(Date:5/25/2016)... , May 25, 2016  According to Kalorama ... $381 billion in 2015.  Though these are challenging ... of opportunity for success for companies that remain ... search of new growth prospects medical device companies ... research and development (R&D) than do companies in ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 27, 2016 , ... Beleza Medspa has initiated a new program ... is the first time that Coolsculpting is being used for for more than just ... ensure they meet the prescribed body-fat standard, measured by the circumference-based tape method. ...
(Date:5/27/2016)... ... May 27, 2016 , ... With ... pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center is ... of successfully certified products, services and staff. , Validation Center is ISO17025 accredited ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... thousands of defective respirators, according to court documents and SEC filings. A ... and Becky Tyler v. American Optical Corporation, Case No. BC588866, Los Angeles County, ...
(Date:5/26/2016)... Washington, D.C. (PRWEB) , ... May 26, 2016 , ... ... the men and women who lost their lives in military battle for the country. ... discount cards in 2015 to provide more programs that empower independence for disabled military ...
(Date:5/26/2016)... ... May 26, 2016 , ... MadgeTech will be showcasing its line of ... Warner, New Hampshire at the MadgeTech headquarters. With products sold in more than 100 ... government agencies, including NASA. , In 2012, NASA strategically set up 17 RHTemp101A ...
Breaking Medicine News(10 mins):